ANI Pharmaceuticals has announced the commercial launch of Flecainide Acetate 50mg, 100mg, and 150mg tablets. The overall US market for Flecainide is $84.8 million, per IMS Health.
Arthur S. Przybyl, President and Chief Executive Officer said, "We are pleased to announce the launch of Flecainide, which marks the successful completion of our product launch plan for 2015. ANI introduced six products in 2015, and we are looking forward to converting additional products from our pipeline to our commercial portfolio in 2016."
About Flecainide Tablets
Flecainide is used for treating and preventing various types of irregular heartbeat that lead to life-threatening heart rhythm disturbances. Flecainide is an antiarrhythmic. It works by stabilizing the heart rhythm when the heart is beating too fast or in an irregular rhythm.